Adding to a portfolio of approved AI algorithms comprising the expansive Viz Platform, a 510(k) clearance from the FDA has been granted to Viz.ai’s Viz Subdural (SDH) artificial intelligence algorithm. The San Francisco-based company was proud to report that its most recently approved algorithm is the only SDH-specific, AI-fueled detection and care coordination platform with the ability to spot acute and chronic subdural bleeding. Moreover, it can run with this knowledge to provide instant notifications to care teams about the dire need for immediate intervention.
“Viz SDH allows us to detect both acute and chronic subdural hemorrhages to better identify early treatment pathways,” said Dr. Jason Davies, associate professor of neurosurgery and biomedical informatics at the State University of New York (SUNY) at Buffalo. “The Viz.ai algorithm ensures that patients are quickly identified and routed to the appropriate therapy.”
A multi-center trial consisting of more than 500 patients met a high standard of accuracy with the benefit of Viz SDH. The AI reached an impressive 94% sensitivity and 92% specificity. The enterprise-wide Viz Platform, having earned clinical validation and reimbursement from Medicare, is now armed with a powerful SDH tool for identifying subdural hemorrhage, which research shows has been growing in commonality among patients.
